Recursion insider plans sale of 100,000 Class A shares
Christopher C. Gibson and related entities filed a notice to sell 100,000 Class A shares of Recursion Pharmaceuticals (RXRX) through Fidelity Brokerage Services, with an aggregate value of $326,754.06, on or after August 10, 2026 on NASDAQ.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Christopher C. Gibson and related entities filed a notice to sell 100,000 Class A shares of Recursion Pharmaceuticals (RXRX) through Fidelity Brokerage Services, with an aggregate value of $326,754.06, on or after August 10, 2026 on NASDAQ.
The filing also lists extensive Class A share sales over the prior three months by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, reflecting multiple transactions ranging from 40,000 to over 340,000 shares per trade.
Key Figures
Key Terms
Form 144 regulatory
compensation financial
Gibson Family Trust financial
Lahwran-3 Llc financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the RXRX Form 144 filed by Christopher C. Gibson disclose?
Which brokerage and market are involved in the RXRX Form 144 sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.